Fig. 6: PRMT1 inhibition reduces NONO arginine methylation and suppresses CRC progression.
From: PRMT1 enhances oncogenic arginine methylation of NONO in colorectal cancer
a Treatment with the PRMT1 inhibitor AMI-1 reduced NONO aDMA level. KM12 and HCT8 cells treated with AMI-1 (1.2 and 0.6 mM) or DMSO for 48 h were subjected to Duolink PLA with anti-ADMA antibody. b AMI-1 treatment reduced tumor xenograft weight (n = 6 mice per group). c Treatment with the PRMT1 inhibitors MS023 and C7280948 decrease aDMA NONO level. KM12 and HCT8 cells were treated with 10 μM MS023 and 40 μM C7280948, respectively, for 48 h, and subjected to NONO IP and western blotting analysis with anti-ADMA antibody. d Treatment with MS023 or C7280948 inhibits CRC cell proliferation. KM12 WT/NONO-KO (2 × 104) and HCT8 WT/NONO-KO (4 × 104) cells were seeded on day 0 and counted on days 2 and 4 after treatment with the indicated inhibitor. KM12 and HCT8 WT/NONO-KO cells treated with MS023 and C7280948 were subjected to the wound-healing assay (e) and transwell assay (f), respectively. For (d–f), MS023, C7280948, or DMSO was added at the time the cells were seeded. Scale bar, 400 μm. *P < 0.05, **P < 0.01, ***P < 0.001.
